The emergence of positive data from trials like PATINA creates a dilemma for oncologists treating patients who are already stable on an older maintenance therapy. The consensus suggests not altering a successful regimen to avoid disrupting patient stability, revealing a cautious approach to integrating new evidence into established care.

When CLL patients temporarily stop their BTK inhibitor for a procedure, they can experience a "disease flare" mimicking relapse. It is critical for clinicians to recognize this phenomenon and not misinterpret it as true disease progression, as symptoms typically resolve upon restarting the medication.

When introducing the overall, multi-year treatment plan at the beginning, it helps patients conceptualize myeloma as a chronic condition rather than a series of acute failures. This reframing prepares them for eventual relapse, reducing devastation and helping them see it as the next step in a long journey.

A study switching therapy based on ctDNA-detected ESR1 mutations revealed patients felt significantly better after the switch, even without visible tumor progression on scans. This counterintuitive finding suggests molecular progression has a subclinical impact on quality of life, supporting proactive, biomarker-driven treatment changes before patients clinically deteriorate.

When PSA levels rise after initial treatments, patients face the difficult realization that their cancer is likely a chronic condition to be managed, not a disease to be cured. This existential moment requires a fundamental shift in their approach and expectations for the rest of their lives.

Dr. Pusztai clarifies the ctDNA lexicon: "Molecular relapse" is when a supposedly cured patient turns ctDNA positive during surveillance. "Molecular progression" is when a metastatic patient on therapy develops new resistance mutations detectable in ctDNA before clinical progression. This specific terminology is key for precise clinical decision-making.

To determine why a BCMA-targeted therapy failed, clinicians are using plasma sequencing assays to check for mutations in the BCMA receptor. The presence of a mutation prompts a switch to a different target rather than retrying a BCMA-directed agent.

As frontline therapies improve and create longer remissions, the first relapse becomes the pivotal moment for treatment. Experts advocate for treating this stage with the same intensity and goals as newly diagnosed disease, including aiming for MRD negativity.

In CLL, Progression-Free Survival (PFS) is a misleading metric for clinical benefit. Time-To-Next-Treatment (TTNT) is often much longer because patients can have biochemical or radiological progression by IWCLL criteria but remain asymptomatic and clinically well, delaying the need for a new therapy.